F-18-FDG and F-18-Florbetapir PET in Clinical Practice Regional Analysis in Mild Cognitive Impairment and Alzheimer Disease

作者：Bailly Matthieu^*; Ribeiro Maria Joao Santiago; Vercouillie Johny; Hommet Caroline; Gissot Valerie; Camus Vincent; Guilloteau Denis

来源：Clinical Nuclear Medicine, 2015, 40(2): E111-E116.

• PET
• F-18-AV45
• florbetapir
• F-18-FDG
• MCI
• Alzheimer disease

Objective: The aim of this study is to compare regional cerebral metabolic rate of glucose metabolism and amyloid-beta density in patients with Alzheimer disease (AD), mild cognitive impairment (MCI), and healthy elderly subjects.
Methods: Eighteen patients (including 6 AD, 5 amnestic MCI, and 7 controls) were enrolled at the University Hospital of Tours, France, and submitted to clinical, neuropsychological, and MRI examinations. PET images using F-18-florbetapir (266 MBq) and F-18-FDG (185 MBq) were acquired. SUV ratios in specific regions were defined using PMOD3.2 software.
Results: The mean values of F-18-FDG SUV ratio were significantly lower in frontal, anterior cingulate, and temporal regions in MCI patients than in normal elderly (-15%, -22%, and -11%, respectively). Alzheimer disease patients showed global cerebral metabolic rate of glucose metabolism decrease, especially in parietal and precuneus regions (-15% and -13% compared with healthy control subjects). Only precuneus cortex showed an increased F-18-florbetapir uptake in AD. There was no other significant regional difference in the amyloid-beta density.
Conclusions: In this study, we observed regional brain metabolic changes between MCI, AD, and controls, whereas only precuneus showed an increased amyloid-beta density in AD. F-18-florbetapir PET analysis needs to be visual and global, whereas F-18-FDG analysis can be regional.

• 出版日期2015-2